Abstract

Aim

In the TORCH trial, molecularly unselected pts with advanced NSCLC were randomized to erlotinib (E) or cisplatin + gemcitabine (CG) as first line within planned treatment sequences. Several biomarkers were studied with exploratory aim. Here we report cMET and PTEN data.

Methods

cMET and PTEN immunohistochemistry (IHC) was performed using standard method and SP44 (Ventana) and 138G6 (Cell Signaling) antibodies, respectively. H-score (intensity x % stained tumor cells) was used to classify cMET IHC (<200) low vs high (≥200) cases. PTEN was scored as IHC- (complete absent) vs IHC+ (any staining). Out of 760 pts in the TORCH study, IHC result was available in 155 for cMET and 148 for PTEN. Interaction between biomarker expression and treatment outcome was tested by Cox model for progression-free survival (PFS) and by Zelen exact test for response rate (RR).

Conclusions

In pts unselected for EGFR mutation and in those with EGFR wt, the relative effect on PFS of E vs CG is less worse among low cMET cases. Objective responses to first line E were only reported among low cMET cases, even if EGFR wt.

Disclosure

M. Tsao: received honoraria on this subject matter from: Roche, AstraZeneca, and received a research grant from Roche; M. Di Maio: acted as consultant or advisory role for Eli Lilly and received honoraria from Eli Lilly and Roche; A. Rossi, P. Maione and C. Gridelli: acted as consultant for Eli Lilli, Roche and received honoraria from Eli Lilli, Roche; C.A. Butts: acted as consultant for Roche and received honoraria from Roche; R. Feld: acted as consultant for Roche, received honoraria from Roche and received a research grant from Roche; F. Perrone: received honoraria from Roche and received a research funding from Roche. All other authors have declared no conflicts of interest.